Chronic Fatigue Syndrome – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of chronic fatigue syndrome (CFS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of CFS for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s CFS forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CFS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts five CFS patient populations:
- Total prevalent cases.
- Total prevalent cases with pain in two or more joints.
- Total prevalent cases with muscle pain.
- Diagnosed prevalent cases.
- Diagnosed prevalent cases with fibromyalgia.
Note: Coverage may vary by country.
Table of contents
- Chronic Fatigue Syndrome - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Total Prevalence of Chronic Fatigue Syndrome per 1,000 Adults in 2021 and 2041
- Total Prevalence of Chronic Fatigue Syndrome per 1,000 Adults in 2021 and 2041
- Relative Sizes of the Factors Contributing to the Trend in Total Prevalent Cases of Chronic Fatigue Syndrome Over the Next 20 Years
- Relative Sizes of the Factors Contributing to the Trend in Total Prevalent Cases of Chronic Fatigue Syndrome Over the Next 20 Years
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Mariam Sophia, M.P.H., Epidemiologist. Prior to studying epidemiology, she had a private clinical practice and later worked as a tutor at Manipal College of Dental Sciences. She has experience working in COVID-19 care centers and in Tele ICU. She holds an M.P.H. from India’s Manipal University, where she specialized in epidemiology. Her research thesis assessed the nutritional status of tribal children less than five years old. She has interned in the government-run tuberculosis program (RNTCP).
Mudasir Khan, M.P.H., Manager, Epidemiology. Before joining Clarivate, Mr. Khan worked as a team lead at IKS Health, an organization that works on patient-level healthcare data management. His areas of expertise at the Clarivate epi team are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.